Business Description
Arcadia Biosciences Inc
NAICS : 311999
SIC : 2099
ISIN : US0390142042
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 10.34 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.06 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -23.9 | |||||
Beneish M-Score | -0.13 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -48.9 | |||||
3-Year EBITDA Growth Rate | 20.5 | |||||
3-Year EPS without NRI Growth Rate | 47.8 | |||||
3-Year FCF Growth Rate | 54.4 | |||||
3-Year Book Growth Rate | -50.5 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 53.78 | |||||
9-Day RSI | 59.47 | |||||
14-Day RSI | 60.17 | |||||
6-1 Month Momentum % | -29.32 | |||||
12-1 Month Momentum % | -55.66 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.05 | |||||
Quick Ratio | 3.41 | |||||
Cash Ratio | 2.95 | |||||
Days Inventory | 249.28 | |||||
Days Sales Outstanding | 42.24 | |||||
Days Payable | 218.67 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -56.4 | |||||
Shareholder Yield % | 25.29 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 33.97 | |||||
Operating Margin % | -246.39 | |||||
Net Margin % | -129.74 | |||||
FCF Margin % | -277.63 | |||||
ROE % | -47.63 | |||||
ROA % | -30.15 | |||||
ROIC % | -249.05 | |||||
ROC (Joel Greenblatt) % | -481.06 | |||||
ROCE % | -68.1 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.71 | |||||
PB Ratio | 0.36 | |||||
Price-to-Tangible-Book | 0.37 | |||||
EV-to-EBIT | 0.28 | |||||
EV-to-EBITDA | 0.28 | |||||
EV-to-Revenue | -0.68 | |||||
EV-to-Forward-Revenue | 0.01 | |||||
EV-to-FCF | 0.25 | |||||
Price-to-Net-Current-Asset-Value | 0.64 | |||||
Price-to-Net-Cash | 1.29 | |||||
Earnings Yield (Greenblatt) % | 355.23 | |||||
FCF Yield % | -377.2 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Arcadia Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 5.006 | ||
EPS (TTM) (€) | -4.671 | ||
Beta | 0.82 | ||
Volatility % | 52.98 | ||
14-Day RSI | 60.17 | ||
14-Day ATR (€) | 0.128483 | ||
20-Day SMA (€) | 2.194 | ||
12-1 Month Momentum % | -55.66 | ||
52-Week Range (€) | 1.75 - 4.78 | ||
Shares Outstanding (Mil) | 1.36 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Arcadia Biosciences Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Arcadia Biosciences Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Arcadia Biosciences Inc Frequently Asked Questions
What is Arcadia Biosciences Inc(FRA:17D)'s stock price today?
When is next earnings date of Arcadia Biosciences Inc(FRA:17D)?
Does Arcadia Biosciences Inc(FRA:17D) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |